ArticleMethods in molecular biology (Clifton, N.J.)2025
Optimization of DOTAP/Cholesterol Cationic Lipid Nanoparticles for Nucleic Acid Delivery.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective delivery methods are essentiel for the successful clinical application of nucleic acids. This chapter outlines a detailed protocol for the preparation, optimization, and characterization of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)/cholesterol (chol) lipid nanoparticles (LNPs) as efficient delivery systems for mRNA, plasmid DNA (pDNA), and oligonucleotides. We describe the formulation of LNPs using a thin-film hydration technique, optimization of key parameters (e.g., DOTAP/Chol ratios, PEGylation, and lipid-to-nucleic acid ratios), and their evaluation using physicochemical and biological assays. This protocol includes methodologies for gel retardation, particle size and zeta potential characterization, in vitro transfection assays, cytotoxicity testing, and long-term stability studies. By following this step-by-step guide, researchers can achieve reproducible results in designing LNPs for various therapeutic applications.
Indexed as
Identifiers
40877514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.